Patient Demographics
| Treatment Cohort . | A . | B . | C . | D . | E . | Total . |
|---|---|---|---|---|---|---|
| r-metHuSCF ( μg/kg/d) | 0 | 5 | 10 | 15 | 20 | |
| Filgrastim ( μg/kg/d) | 10 | 10 | 10 | 10 | 10 | |
| Age (yr) | ||||||
| N | 11 | 6 | 6 | 7 | 8 | 38 |
| Median | 51.0 | 51.0 | 45.0 | 55.0 | 48.5 | 49.0 |
| Range | 21.0-61.0 | 26.0-63.0 | 23.0-58.0 | 41.0-59.0 | 29.0-61.0 | 21.0-63.0 |
| Sex | ||||||
| Men | 6 | 6 | 5 | 5 | 6 | 28 |
| Women | 5 | 0 | 1 | 2 | 2 | 10 |
| Karnofsky performance | 90-100 | 80-100 | 80-100 | 80-100 | 90-100 | 80-100 |
| Status range (median) | (100) | (100) | (85) | (90) | (90) | (90) |
| Disease stage at enrollment | ||||||
| II | 1 | 0 | 3 | 1 | 1 | 6 |
| IIE | 0 | 0 | 0 | 0 | 1 | 1 |
| III | 4 | 2 | 0 | 1 | 0 | 7 |
| IIIE | 1 | 0 | 0 | 0 | 2 | 3 |
| IV | 5 | 3 | 3 | 5 | 3 | 19 |
| Chemosensitive disease in first relapse | 5 | 4 | 5 | 4 | 4 | 22 |
| Second remission | 5 | 2 | 1 | 3 | 3 | 14 |
| Treatment Cohort . | A . | B . | C . | D . | E . | Total . |
|---|---|---|---|---|---|---|
| r-metHuSCF ( μg/kg/d) | 0 | 5 | 10 | 15 | 20 | |
| Filgrastim ( μg/kg/d) | 10 | 10 | 10 | 10 | 10 | |
| Age (yr) | ||||||
| N | 11 | 6 | 6 | 7 | 8 | 38 |
| Median | 51.0 | 51.0 | 45.0 | 55.0 | 48.5 | 49.0 |
| Range | 21.0-61.0 | 26.0-63.0 | 23.0-58.0 | 41.0-59.0 | 29.0-61.0 | 21.0-63.0 |
| Sex | ||||||
| Men | 6 | 6 | 5 | 5 | 6 | 28 |
| Women | 5 | 0 | 1 | 2 | 2 | 10 |
| Karnofsky performance | 90-100 | 80-100 | 80-100 | 80-100 | 90-100 | 80-100 |
| Status range (median) | (100) | (100) | (85) | (90) | (90) | (90) |
| Disease stage at enrollment | ||||||
| II | 1 | 0 | 3 | 1 | 1 | 6 |
| IIE | 0 | 0 | 0 | 0 | 1 | 1 |
| III | 4 | 2 | 0 | 1 | 0 | 7 |
| IIIE | 1 | 0 | 0 | 0 | 2 | 3 |
| IV | 5 | 3 | 3 | 5 | 3 | 19 |
| Chemosensitive disease in first relapse | 5 | 4 | 5 | 4 | 4 | 22 |
| Second remission | 5 | 2 | 1 | 3 | 3 | 14 |